Literature DB >> 26600122

The interaction of Mozobil™ with carboxylates.

Valeria Amendola1, Greta Bergamaschi, Luigi Fabbrizzi, Maurizio Licchelli, Carlo Mangano.   

Abstract

Mozobil(™) (1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane], 1, also known as JM3100 and AMD 3100) is a specific antagonist of the chemokine coreceptor CXCR4 and favours the mobilisation from the bone marrow of stem cells, which can be used for autologous transplantation. It is believed that the interaction, of both hydrogen bonding and electrostatic nature, involves a partly protonated form of Mozobil(™), LHn(n+) and the COO(-) groups of Asp(171) and Asp(262) residues protruding from the walls of the pocket of the membrane protein CXCR4. We have investigated, through potentiometric titrations in 0.1 M NaNO3 at 25 °C, the interaction equilibria between 1 (L) and linear dicarboxylates A(2-). These studies have demonstrated that the main equilibrium takes place: LH5(5+) + A(2-)⇄ [LH5···A](3+), and that the most stable [LH5···A](3+) complex forms for A(2-) = diphenyl-4,4'-dicarboxylate, whose length matches that of LH5(5+). (1)H NMR titration experiments have shown that in the 7-10 pH interval, LH3(3+), LH2(2+) and LH(+) forms establish π-π interactions with diphenyl-4,4'-dicarboxylate, according to a topological arrangement which excludes the formation of H-bonds. It is finally suggested that, in the pocket of the CXCR4 membrane protein, Mozobil(™) operates as a pentammonium cation, which establishes with carboxylate groups of Asp(171) and Asp(262) strong interactions of hydrogen bonding and electrostatic nature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26600122     DOI: 10.1039/c5ob01704a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  1 in total

1.  Towards Building Blocks for Supramolecular Architectures Based on Azacryptates.

Authors:  Ana Miljkovic; Sonia La Cognata; Greta Bergamaschi; Mauro Freccero; Antonio Poggi; Valeria Amendola
Journal:  Molecules       Date:  2020-04-09       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.